Targeting hepatic glucose metabolism in the treatment of type 2 diabetes

被引：301

作者：

Rines, Amy K.

Sharabi, Kfir

Tavares, Clint D. J.

Puigserver, Pere ^{[1
]}

机构：

[1] Harvard Med Sch, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 11期

基金：

美国国家卫生研究院;

关键词：

GLYCOGEN-SYNTHASE KINASE-3; GLUCAGON RECEPTOR ANTAGONIST; SMALL-MOLECULE INHIBITORS; PHOSPHATASE 1B PTP1B; LOWERS BLOOD-GLUCOSE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; HEPATOSELECTIVE GLUCOKINASE ACTIVATOR; INSULIN-RESISTANCE; PHOSPHORYLASE INHIBITOR; GLYCEMIC CONTROL;

D O I：

10.1038/nrd.2016.151

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia. Although current diabetes treatments have exhibited some success in lowering blood glucose levels, their effect is not always sustained and their use may be associated with undesirable side effects, such as hypoglycaemia. Novel antidiabetic drugs, which may be used in combination with existing therapies, are therefore needed. The potential of specifically targeting the liver to normalize blood glucose levels has not been fully exploited. Here, we review the molecular mechanisms controlling hepatic gluconeogenesis and glycogen storage, and assess the prospect of therapeutically targeting associated pathways to treat type 2 diabetes.

引用

页码：786 / 804

页数：19

共 252 条

[1] Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose [J].